The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond-Reference-Cited by-同舟云学术

The Sacubitril/Valsartan, a First-in-Class, Angiotensin Receptor Neprilysin Inhibitor (ARNI): Potential Uses in Hypertension, Heart Failure, and Beyond

Published:2018-01 Issue:1 Volume:20 Page:
ISSN:1523-3782
Container-title:Current Cardiology Reports
language:en
Short-container-title:Curr Cardiol Rep

Author:

Kario Kazuomi

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine

Link

http://link.springer.com/article/10.1007/s11886-018-0944-4/fulltext.html

Reference55 articles.

1. McMurray JJ, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993–1004.

2. Ruilope LM, Dukat A, Bohm M, Lacourciere Y, Gong J, Lefkowitz MP. Blood-pressure reduction with SACUBITRIL/VALSARTAN, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet. 2010;375:1255–66.

3. Kario K, Sun N, Chiang FT, Supasyndh O, Baek SH, Inubushi-Molessa A, et al. Efficacy and safety of SACUBITRIL/VALSARTAN, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: A randomized, double-blind, placebo-controlled study. Hypertension. 2014;63:698–705.

4. Kario K. Proposal of a new strategy for ambulatory blood pressure profile-based management of resistant hypertension in the era of renal denervation. Hypertens Res. 2013;36:478–84.

5. Williams B, Cockcroft JR, Kario K, Zappe DH, Cardenas P, Hester A, et al. Rationale and study design of the Prospective comparison of Angiotensin Receptor neprilysin inhibitor with Angiotensin receptor blocker MEasuring arterial sTiffness in the eldERly (PARAMETER) study. BMJ Open. 2014;4:e004254.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multi-Target In-Silico modeling strategies to discover novel angiotensin converting enzyme and neprilysin dual inhibitors;Scientific Reports;2024-07-10

2. Pseudo-nephropathy and hyper-excretion of urinary C-peptide: an overlooked adverse effect of an angiotensin receptor–neprilysin inhibitor (ARNI);Diabetology International;2024-05-28

3. Comparison of sacubitril/valsartan with olmesartan for hypertension: A meta-analysis of randomized controlled trials;Medicine;2024-04-05

4. Sacubitril/valsartan reversal of left ventricular remodeling is associated with improved hemodynamics in resistant hypertension;Hellenic Journal of Cardiology;2024-04

5. The recent advance and prospect of natural source compounds for the treatment of heart failure;Heliyon;2024-03